Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harvard BioscienceFRA:HBI0 53 Current Ratio is 1.87 as of Jun. 2026, which is 18% below its 10-year median of 2.27. GuruFocus rates FRA:HBI0 with a GF Score™ of 53/100 and a GF Value™ of €6.70. The stock has 9 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Harvard Bioscience ranks worse than 64.16% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Harvard Bioscience's current ratio for the quarter that ended in Jun. 2026 was 1.87.
Harvard Bioscience has a current ratio of 1.87. It generally indicates good short-term financial strength.
The historical rank and industry rank for Harvard Bioscience's Current Ratio or its related term are showing as below:
FRA:HBI0'
s Current Ratio Range Over the Past 10 Years
Min: 0.81 Med: 2.27 Max: 3.46
Current: 1.87
During the past 13 years, Harvard Bioscience's highest Current Ratio was 3.46. The lowest was 0.81. And the median was 2.27.
FRA:HBI0's Current Ratio is ranked worse than 64.16% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 2.43
vs FRA:HBI0: 1.87
Harvard Bioscience (FRA:HBI0) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Harvard Bioscience Current Ratio Related Terms
Harvard Bioscience Current Ratio Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HBI0 vs RVP, MLSS, ZJYL: Current Ratio Comparison
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Current Ratio distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience (FRA:HBI0) has a Current Ratio of 1.87 as of Jun. 2026. This is 18% below median its historical median of 2.27. Over the past decade, Harvard Bioscience's Current Ratio has ranged from 0.81 to 3.46. According to the industry distribution chart, Harvard Bioscience ranks #546 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 64.2%.
Is Harvard Bioscience's Current Ratio too high?
Harvard Bioscience's current Current Ratio of 1.87 is 18% below median its 10-year median of 2.27. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 3.46. The Medical Devices & Instruments industry median Current Ratio is 2.43. Harvard Bioscience's value of 1.87 is 23% below this industry median. Based on the distribution chart, Harvard Bioscience ranks #546 out of 851 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Harvard Bioscience has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Current Ratio compare to RVP and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #546 out of 851 companies for Current Ratio. This places Harvard Bioscience in the lower half of its industry. The industry median Current Ratio is 2.43. Harvard Bioscience's value of 1.87 is 23% below this benchmark. Historically, Harvard Bioscience's own Current Ratio has ranged from 0.81 to 3.46 over the past decade. While the company's 10-year median is 2.27 vs. the industry median of 2.43, Harvard Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.43, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harvard Bioscience's current Current Ratio of 1.87 is 23% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current Current Ratio is 1.87, which is 18% below median its own 10-year median of 2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current Current Ratio of 1.87. The stock's GF Value™ is €6.70, compared to a current price of €4.08 — trading 39.1% below its estimated fair value. The current Current Ratio is 1.87, which is 18% below median its 10-year median of 2.27 and 23% below the Medical Devices & Instruments industry median of 2.43. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current Current Ratio is 1.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of €4.08 is trading 39.1% below its estimated GF Value™ of €6.70.
Key valuation signals for FRA:HBI0:
Current Ratio: 1.87 (18% below median its 10-year median of 2.27)
GF Value™: €6.70 vs. price of €4.08 (39.1% below fair value)
Industry Position: 23% below the Medical Devices & Instruments median (#546 of 851)
No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score
Get the complete analysis for FRA:HBI0
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HBI0 has been successfully added to your 
